Kidney cancer in the elderly

Urologic Oncology: Seminars and Original Investigations

Volumn 27, Issue 6, 2009, Pages 673-676

  Kirkali, Ziya ^a  

^a DOKUZ EYLUL UNIVERSITY   (Turkey)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT;

CANCER CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER SURGERY; CANCER SURVIVAL; COMORBIDITY; GERIATRIC CARE; HUMAN; KIDNEY CANCER; METASTASIS; PRIORITY JOURNAL; REVIEW; TREATMENT PLANNING;

AGE FACTORS; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; CARCINOMA, RENAL CELL; HUMANS; KIDNEY NEOPLASMS; LIFE EXPECTANCY; PATIENT SELECTION; RISK ASSESSMENT; RISK FACTORS; SURGICAL PROCEDURES, MINIMALLY INVASIVE; SURVIVAL RATE; TREATMENT OUTCOME; UROLOGIC SURGICAL PROCEDURES;

EID: 70350494077     PISSN: 10781439     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.urolonc.2009.07.016     Document Type: Review

References (37)

1. U.S. Interim Projection by Age, Sex, Race, and Hispanic Origin. www.census.gov/ipc/www/usinterimpro/ Accessed on March 25, 2008
2. Kirkali Z., and Lekili M. Renal cell carcinoma: New prognostic factors?. Curr Opinion in Urol 13 (2003) 433-438
3. Selle B., Furtwangler R., Graf N., et al. Population-based study of renal cell carcinoma in children in Germany, 1980-2005. More frequently localized tumors and underlying disorders compared with adult counterparts. Cancer 107 (2006) 2906-2914
4. Cao Y., Paner G.P., Perry K.T., et al. Renal neoplasms in younger adults. Analysis of 112 tumors from a single institution according to the new 2004 World Health Organization Classification and 2002 American Joint Committee on Cancer Staging System. Arch Pathol Lab Med 129 (2005) 487-491
5. Eggener S.E., Rubenstein J.R., Smith N.D., et al. Renal tumors in young adults. J Urol 171 (2004) 106-110
6. El Fettouh H.I.A., Cherullo E.E., El-Jack M., et al. Sporadic renal cell carcinoma in young adults: Presentation, treatment, and outcome. Urology 60 (2002) 806-810
7. Masuda H, Kurita Y, Suzuki A, et al. Prognostic factors for renal cell carcinoma: A multivariate analysis of 320 cases. Int J Urol 1007;4:247-53.
8. Yusim I., Mermershtain W., Neulander E., et al. Influence of age on the prognosis of patients with renal cell carcinoma (RCC). Onkologie 25 (2002) 548-550
9. Griffiths D.F.R., Verghese A., Golash A., et al. Contribution of grade, vascular invasion, and age to outcome in clinically localized renal cell carcinoma. BJU Int 90 (2002) 26-31
10. Sanchez-Ortiz R.F., Rosser C.J., Madsen L.T., et al. Young age is an independent prognostic factor for survival of sporadic renal cell carcinoma. J Urol 171 (2004) 2160-2165
11. Denzinger S., Otto W., Burger M., et al. Sporadic renal cell carcinoma in young and elderly patients: Are there different clinicopathologic features and disease specific survival rates. World J Surg Oncol 5 (2007) 16
12. Taccoen X., Valeri A., Descotes J.L., et al. Renal cell carcinoma in adults 40 years old or less: Young age is an independent prognostic factor for cancer-specific survival. Eur Urol 51 (2007) 980-987
13. Verhoest G., Veillard D., Guille F., et al. Relationship between age at diagnosis and clinicopathological features of renal cell carcinoma. Eur Urol 51 (2007) 1298-1305
14. Thoroddsen A., Einarsson G.V., Hardarson S., et al. Renal cell carcinoma in young compared to older patients: Comparison of clinicopathologic risk factors and survival. Scand J Urol Nephrol 42 (2008) 121-125
15. Doherty J.G., Rufer A., Bartholomew P., et al. The presentation, treatment, and outcome of renal cell carcinoma in old age. Age and Aging 28 (1999) 359-362
16. Rodriguez A., Patard J.J., and Lobel B. Renal cell carcinoma in young adults: Incidence, disease outcome, and review of the literature. Arch Esp Urol 55 (2002) 969-975
17. Goetzl M.A., Deasai M., Mansukhani M., et al. Natural history and clinical outcome of sporadic renal cortical tumors diagnosed in the young adult. Urology 63 (2004) 41-45
18. Gillet M.D., Cheville J.C., Karnes R.J., et al. Comparison of presentation and outcome for patients 18 to 40 and 60 to 70 years old with solid renal masses. J Urol 173 (2005) 1893-1896
19. Zugor V., Fridel S., Lausen B., et al. Renal cell carcinoma under 35 years of age: Comparison of survival rates for symptomatic and asymptomatic patients. Int Urol Nephrol 40 (2008) 289-293
20. Gomez-Perez L., Budia-Alba A., Delgadon-Oliva F.J., et al. Renal cancer in the elderly: Clinical and histopathologic findings. Acta Urol Esp 30 (2006) 139-144
21. Charlson ME, Pompei P, Ales KL, et al. A new method of classifying prognostic comorbidity in longitudinal studies: Development and validation. J Chronic Dis 1087;40:373-83.
22. Gettman M.T., Boelter C.W., Cheville J.C., et al. Charlson comorbidity index as a predictor of outcome after surgery for renal cell carcinoma with renal vein, vena cava, or right atrium extension. J Urol 169 (2003) 1282-1286
23. Hall J.C., and Hall J.L. ASA status and age predict adverse events after abdominal surgery. J Qual Clin Pract 16 (1996) 103-108
24. Berdjis N., Hakenberg O.W., Novotny V., et al. Treating renal cancer in the elderly. BJU Int 97 (2006) 703-705
25. Damhuis R.A., and Blom J.H. The influence of age on treatment choice and survival in 735 patients with renal carcinoma. Br J Urol 75 (1995) 143-147
26. Cobb W.S., Heniford B.T., Mathews B.D., et al. Advanced age is not a prohibitive factor in laparoscopic nephrectomy for renal pathology. Am Surg 70 (2004) 537-542
27. Hsu T.H.S., Gill I.S., Fazeli-Matin S., et al. Radical nephrectomy and nephroureterectomy in the octogenarian and nonagenarian: Comparison of laparoscopic and open approaches. Urology 53 (1999) 1121-1125
28. Varkarakis I., Neururer R., Harabayashi T., et al. Laparoscopic radical nephrectomy in the elderly. BJU Int 94 (2004) 517-520
29. Mouraviev V., Joniau S., Van Poppel H., et al. Current status of minimally invasive ablative techniques in the treatment of small renal tumours. Eur Urol 51 (2007) 296-298
30. Kader A.K., Tamboli P., Luongo T., et al. Cytoreductive nephrectomy in the elderly patient: The M. D. Anderson Cancer Center experience. J Urol 177 (2007) 855-861
31. Govorov A., and Pushkar D. Cancer in the elderly: What is different?. Eur Urol 7 Suppl (2008) 447-455
32. Atzpodien J., Wandert T., and Reitz M. Age does not impair the efficacy of immunochemotherapy in patients with metastatic renal carcinoma. Crit Rev Oncol Hematol 55 (2005) 193-199
33. Motzer R.J., Hutson T.E., Tomczak P., et al. Sunitinib versus interferon-α in metastatic renal cell carcinoma. N Engl J Med 356 (2007) 115-124
34. Escudier B., Eisen T., Stadler W.M., et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 356 (2007) 125-134
35. Hudes G., Carducci M., Tomczak P., et al. Temsirolimus, interferon-α, or both for advanced renal-cell carcinoma. N Engl J Med 356 (2007) 2271
36. Escudier B., Pluzanska A., Koralewski P., et al. Bevacizumab plus interferon α-2a for treatment of metastatic renal cell carcinoma: A randomized, double-blind phase III trial. The Lancet 370 (2008) 2103-2111
37. Pond G.R., Siu L.L., Moore M., et al. Nomograms to predict serious adverse events in phase II clinical trials of molecularly targeted agents. J Clin Oncol 26 (2008) 1324-1330